Fortrea Company Research Report

Company Overview

• Name: Fortrea

• Mission: Bringing life-changing treatments to patients faster with exceptional experiences in clinical development.

• Founded: No information is available

• Founder(s): No information is available

• Key People: Oren Cohen, MD, FIDSA, Chief Medical Officer

• Headquarters: No information is available

• Number of Employees: No information is available

• Revenue: No information is available

• Known For: Fortrea is known for redefining delivery through innovation, providing comprehensive Phase I through IV study management, clinical pharmacology, and market access solutions to biopharma and MedTech companies worldwide.

Products

Fortrea primarily offers services, as indicated by the information provided.

• Clinical Solutions:

• Fortrea provides creative problem-solving through clinical development, technology, and patient access solutions.

• Key Features: Scalable and flexible delivery models, tailored clinical solutions.

• Therapeutic Specialties:

• Expertise in multiple therapeutic areas including Oncology, Neuroscience, Ophthalmology, Cardiovascular, Diabetes & Endocrinology, and more.

• Key Features: Specialized expertise to navigate complex clinical trials, patient-focused approach.

• Safety & Pharmacovigilance:

• Ensures patient safety across all phases, from trial startup to post-market.

• Key Features: Integrated pharmacovigilance services, real-time safety data management.

• Consulting:

• Support for regulatory strategy, product development, market access, and HEOR.

• Key Features: Agile and flexible consulting across the product development continuum.

Recent Developments

• 2024: Fortrea focuses on core CRO services and value creation by spinning off FortreaRx™, patient access services, and Endpoint Clinical.

• 2023: Fortrea spun off from Labcorp to focus on being a leading clinical services provider.

• 2020 - 2021 Developments:

• Acquired technology to support decentralized clinical trials.

• Acquired remote nursing offering.

• Expanded into the MedTech market with the acquisition of RCRI.

• Enhanced biotech expertise by acquiring Chiltern, Endpoint Clinical, and other pharmacovigilance capabilities.

• Innovations and Strategies:

• Fortrea is driving a service delivery evolution with solutions that enable faster decision-making and exceptional customer experiences.

• Recent technological advancements in liquid biopsy and immuno-oncology reflect their commitment to continuous innovation.

• Partnerships and Collaborations:

• Fortrea emphasizes strong collaborations with pharmaceutical and biotechnology partners to conduct phase-specific clinical trials.

• Emphasis on site connections to streamline clinical research and focus on trial participant care.

Conclusion

Fortrea is a leader in the clinical research organization (CRO) space, with over 30 years of expertise. The company continuously innovates and adapts to meet the dynamic needs of the healthcare industry, focusing on therapeutic insights, patient-centric approaches, and strategic partnerships to deliver life-changing treatments efficiently and effectively.